{
    "nct_id": "NCT05358938",
    "official_title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
    "inclusion_criteria": "* Age â‰¥ 18 years\n* Able to read and speak English fluently\n* Capable of giving informed consent\n* Reported ability to complete 20-30 minutes moderate exercise per positive response to \"can you currently walk unaided for six minutes or more?\".\n* Scheduled for first-time checkpoint blockade immunotherapy with FDA-approved drugs, including avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab or relatlimab in the absence of other therapies (e.g. targeted therapy)\n* Melanoma patients (adjuvant setting)\n* Melanoma patients (neoadjuvant setting)\n* cuSCC patients (neoadjuvant setting)\n* Merkel cell carcinoma patients (neoadjuvant setting)\n\nParticipants may also be required to have a full COVID vaccination series; the most up-to-date best practice guidelines for research at Moffitt Cancer Center will dictate the need for such a vaccination series.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of medical conditions, such as severe cardiovascular disease for which an exercise intervention may not be warranted.\n* Presence of major postoperative complications for which an exercise intervention may not be warranted.",
    "miscellaneous_criteria": "*"
}